Multinational phase 1 trial of talquetemab for relapsed or refractory multiple myeloma

G-protein-coupled receptor, family C, group 5, member D (GPRC5D) is an orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells. A multinational phase 1 trial evaluated talquetamab for heavily pretreated (median six previous lines of therapy) relapsed or refractory multiple myeloma. Common adverse events were cytokine release syndrome, skin-related events, and disgeusia, but were primarily low-grade. Talquetamab induced a substantial response at the recommended phase 2 dose (quick take video summary).